ArticleThoracic cancer2023

Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.

Ling Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.